• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
3-Bromo-4-fluorobenzaldehyde
5-Methyl-1,3,4-oxadiazol2(3H)-one
4-Amino-6-methyl-3 oxo2,3, 4,5-tetrahydro 1.2.4-triazine hydrochloride
4-Acetylamino-6-methyl -3-oxo-2,3,4,5-tetrahydro-1,2,4-triazine
3-Pyridinecarboxaldehyde
Ethyl 3 Fluorobenzoate

Over 1.16b Chinese fully vaccinated against COVID-19

NMPA/XinhuaDecember 14, 2021

Tag: Chinese , COVID-19 , Vaccine

Over 1.16 billion Chinese people have been fully vaccinated against COVID-19, a spokesperson for the National Health Commission said at a press conference on Dec 11.

A total of 2.59 billion COVID-19 vaccine doses had been administered as of Friday, said Mi Feng, a spokesperson for the commission.

Previous:Brii Bio’s tests show combo therapy retains activity against Omicron

Next:Lilly and Foghorn Announce Strategic Collaboration for Novel Oncology Targets Using Foghorn's Proprietary Gene Traffic Control® Platform

Related News

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

BioPharmaSpec, the leading global Contract Research Organization (CRO) for Discovery and Preclinical Characterization of Biopharmaceuticals, has officially announced three new European facilities.

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Over 1.16b Chinese fully vaccinated against COVID-19 | Pharmasources.com

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

PharmaSourcesNovember 15, 2024

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

You may like
More>>

ZRJ Series Wetting Maching Of Chinese Traditional Medicine

ZRJ Series Wetting Maching Of Chinese Traditional Medicine
Rabies Vaccine(Vero Cell)for Human use

Rabies Vaccine(Vero Cell)for Human use
Chinese Mosla Herb Extract

Chinese Mosla Herb Extract
Hualan Biological Meningococcal Polysaccharide Vaccine Group ACYW135

Hualan Biological Meningococcal Polysaccharide Vaccine Group ACYW135
Automatic GMP Washing and Drying System Meet Requirement of Pharmaceutical and Vaccine Production

Automatic GMP Washing and Drying System Meet Requirement of Pharmaceutical and Vaccine Production
Gold supplier Chinese hawthorn fruit extract

Gold supplier Chinese hawthorn fruit extract
Hot Selling Chinese Taxillus Herb Extract

Hot Selling Chinese Taxillus Herb Extract

Factory Supply Chinese Taxillus Herb Extract

Factory Supply Chinese Taxillus Herb Extract

Trivalent Vaccine

Trivalent Vaccine
Pure Herbage Rosemary Oil Price from Chinese Suppliers

Pure Herbage Rosemary Oil Price from Chinese Suppliers

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service